Insulet Share Price Today
(NASDAQ: PODD)

Name: Insulet Share Price Today (NASDAQ: PODD) - Insulet Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Insulet share price is $282.8 & ₹24,526.11 as on 22 Feb 2025, 2.30 'hrs' IST

$282.8

▲

-5.49

(-1.9%)

Market is closed - opens 8 PM, 24 Feb 2025

View live Insulet share price in Dollar and Rupees. Guide to invest in Insulet stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Insulet, along with analyst recommendations, forecasts, and comprehensive financials.

Insulet share price movements

Today's Low: $275.32
Today's High: $286.45
$282.80
2.64%
Downside
Day's Volatility :3.88%
Upside
1.27%
52 Weeks Low: $160.19
52 Weeks High: $289.46
$282.80
43.36%
Downside
52 Weeks Volatility :44.66%
Upside
2.3%

Insulet (PODD) Returns

Period	Insulet Corporation	Sector (Health Care)	Index (Russel 2000)
3 Months	6.08%	1.6%	0.0%
6 Months	56.51%	-5.8%	0.0%
1 Year	67.51%	-1.0%	0.0%
3 Years	7.79%	15.7%	-9.0%

Insulet (PODD) Key Statistics

in dollars & INR

Previous Close	$288.29
Open	$276.35
Today's High	$286.447
Today's Low	$275.32
Market Capitalization	$19.8B
Today's Volume	$1.4M
52 Week High	$289.46
52 Week Low	$160.19
Revenue TTM	$2.1B
EBITDA	$388.0M
Earnings Per Share (EPS)	$5.77
PE Ratio	49.01
Profit Margin	20.19%
Quarterly Earnings Growth YOY	-0.06%
Return On Equity TTM	43.03%

How to invest in Insulet Stock (PODD) from India?

It is very easy for Indian residents to invest directly in Insulet from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Insulet stock in both Indian Rupees (INR) and US Dollars (USD). Search for Insulet or PODD on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Insulet or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Insulet shares which would translate to 0.003 fractional shares of Insulet as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Insulet, in just a few clicks!

Returns in Insulet (PODD) for Indian investors in Rupees

The Insulet stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Insulet investment value today

Current value as on today

₹1,72,155

Returns

₹72,155

(+72.16%)

Returns from Insulet Stock

₹67,506 (+67.51%)

Dollar Returns

₹4,649 (+4.65%)

Indian investors sentiment towards Insulet (PODD)

-44%

Period: Jan 24, 2025 to Feb 23, 2025. Change in 30 Days versus previous period

Search interest for Insulet Stock from India on INDmoney has decreased by -44% in the last 30 days, reflecting a downward trend in search activity.

Indian Mutual Funds that invest in Insulet Stock (PODD Ticker)

Name	Shares Held	Change in Shares	% of Assets
Motilal Oswal S&P 500 Index Fund Direct Growth	605	1.66	0.04%

Global Institutional Holdings in Insulet

Vanguard Group Inc
12.10%
FMR Inc
11.36%
Capital Research Global Investors
10.62%
BlackRock Inc
8.53%
State Street Corp
4.16%
Baillie Gifford & Co Limited.
3.36%

Analyst Recommendation on Insulet

Buy

82%Buy

17%Hold

0%Sell

Based on 28 Wall street analysts offering stock ratings for Insulet(by analysts ranked 0 to 5 stars)

Based on 28 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Insulet Stock (PODD)

What analysts predicted

Upside of 9.19%

Target:

$308.79

Current:

$282.80

Insights on Insulet Stock (Ticker Symbol: PODD)

Price Movement
In the last 6 months, PODD stock has moved up by 52.8%
Increasing Revenue
Revenue is up for the last 2 quarters, 372.6M → 597.5M (in $), with an average increase of 37.6% per quarter
Increasing Net Profit
Netprofit is up for the last 2 quarters, 77.5M → 100.7M (in $), with an average increase of 23.0% per quarter
PODD vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 56.0% return, outperforming this stock by 2.5%
PODD vs BSX (3 yr)
In the last 3 years, Boston Scientific Corp. has given 139.1% return, outperforming this stock by 116.6%
Price to Sales
ForPODD every $1 of sales, investors are willing to pay $9.6, whereas for Boston Scientific Corp., the investors are paying $9.2 for every $1 of sales.

PODD Insulet Financials in INR & Dollars

	FY19	Y/Y Change
Revenue	$738.2M	↑ 30.93%
Net Income	$11.6M	↑ 252.37%
Net Profit Margin	1.57%	↑ 0.99%

	FY20	Y/Y Change
Revenue	$904.4M	↑ 22.51%
Net Income	$6.8M	↓ 41.38%
Net Profit Margin	0.75%	↓ 0.82%

	FY21	Y/Y Change
Revenue	$1.1B	↑ 21.49%
Net Income	$16.8M	↑ 147.06%
Net Profit Margin	1.53%	↑ 0.78%

	FY22	Y/Y Change
Revenue	$1.3B	↑ 18.79%
Net Income	$4.6M	↓ 72.62%
Net Profit Margin	0.35%	↓ 1.18%

	FY23	Y/Y Change
Revenue	$1.7B	↑ 30.02%
Net Income	$206.3M	↑ 4384.78%
Net Profit Margin	12.16%	↑ 11.81%

	FY24	Y/Y Change
Revenue	$2.1B	↑ 22.07%
Net Income	$418.3M	↑ 102.76%
Net Profit Margin	20.19%	↑ 8.03%

	Q3 FY23	Q/Q Change
Revenue	$432.7M	↑ 9.13%
Net Income	$51.9M	↑ 90.11%
Net Profit Margin	11.99%	↑ 5.1%

	Q4 FY23	Q/Q Change
Revenue	$509.8M	↑ 17.82%
Net Income	$103.3M	↑ 99.04%
Net Profit Margin	20.26%	↑ 8.27%

	Q1 FY24	Q/Q Change
Revenue	$441.7M	↓ 13.36%
Net Income	$51.5M	↓ 50.15%
Net Profit Margin	11.66%	↓ 8.6%

	Q2 FY24	Q/Q Change
Revenue	$488.5M	↑ 10.6%
Net Income	$188.6M	↑ 266.21%
Net Profit Margin	38.61%	↑ 26.95%

	Q3 FY24	Q/Q Change
Revenue	$372.6M	↓ 23.73%
Net Income	$77.5M	↓ 58.91%
Net Profit Margin	20.8%	↓ 17.81%

	Q4 FY24	Q/Q Change
Revenue	$597.5M	↑ 60.36%
Net Income	$100.7M	↑ 29.94%
Net Profit Margin	16.85%	↓ 3.95%

	FY19	Y/Y Change
Profit	$480.3M	↑ 29.75%

	FY20	Y/Y Change
Profit	$582.3M	↑ 21.24%

	FY21	Y/Y Change
Profit	$752.1M	↑ 29.16%

	FY22	Y/Y Change
Profit	$805.6M	↑ 7.11%

	FY23	Y/Y Change
Profit	$1.2B	↑ 43.98%

	FY24	Y/Y Change
Profit	$1.4B	↑ 24.64%

	Q3 FY23	Q/Q Change
Profit	$293.3M	↑ 10.72%

	Q4 FY23	Q/Q Change
Profit	$361.2M	↑ 23.15%

	Q1 FY24	Q/Q Change
Profit	$309.9M	↓ 14.2%

	Q2 FY24	Q/Q Change
Profit	$334.2M	↑ 7.84%

	Q3 FY24	Q/Q Change
Profit	$377.1M	↑ 12.84%

	Q4 FY24	Q/Q Change
Profit	$430.9M	↑ 14.27%

	FY19	Y/Y Change
Operating Cash Flow	$98.4M	↑ 174.1%
Investing Cash Flow	$-73.6M	↓ 60.11%
Financing Cash Flow	$73.5M	↓ 948.24%

	FY20	Y/Y Change
Operating Cash Flow	$84.0M	↓ 14.63%
Investing Cash Flow	$14.0M	↓ 119.02%
Financing Cash Flow	$605.5M	↑ 723.81%

	FY21	Y/Y Change
Operating Cash Flow	$-68.1M	↓ 181.07%
Investing Cash Flow	$-82.7M	↓ 690.71%
Financing Cash Flow	$40.7M	↓ 93.28%

	FY22	Y/Y Change
Operating Cash Flow	$119.0M	↓ 274.74%
Investing Cash Flow	$-191.1M	↑ 131.08%
Financing Cash Flow	$-40.3M	↓ 199.02%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$44.0M	↑ 8700.0%
Investing Cash Flow	$-23.1M	↓ 45.13%
Financing Cash Flow	$3.2M	↓ 126.45%

Insulet Technicals Summary

Sell

Neutral

Buy

Insulet is currently in a neutral trading position according to technical analysis indicators.

Insulet (PODD) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Insulet Corporation	2.5%	56.51%	67.51%	7.79%	57.1%
Medtronic Plc	-0.28%	0.67%	7.49%	-15.02%	-15.27%
Edwards Lifesciences Corp.	6.25%	6.62%	-14.92%	-35.15%	-0.76%
Boston Scientific Corp.	2.5%	31.48%	56.73%	131.69%	165.27%
Stryker Corporation	-2.92%	8.04%	8.6%	44.02%	89.81%
Abbott Laboratories	7.91%	19.72%	13.67%	10.22%	65.83%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Insulet Corporation	49.01	49.01	4.28	4.25	0.43	0.07	NA	17.27
Medtronic Plc	26.81	26.81	1.48	5.45	0.08	0.05	0.03	38.49
Edwards Lifesciences Corp.	31.32	31.32	5.83	2.45	0.17	0.11	NA	16.18
Boston Scientific Corp.	84.29	84.29	1.88	2.86	0.09	0.05	NA	14.76
Stryker Corporation	49.73	49.73	2.71	13.51	0.15	0.07	0.01	54.1
Abbott Laboratories	17.43	17.43	2.38	5.15	0.34	0.06	0.02	22.94

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Insulet Corporation	Buy	$19.8B	57.1%	49.01	20.19%
Medtronic Plc	Buy	$112.9B	-15.27%	26.81	12.83%
Edwards Lifesciences Corp.	Buy	$43.2B	-0.76%	31.32	76.75%
Boston Scientific Corp.	Buy	$155.5B	165.27%	84.29	11.07%
Stryker Corporation	Buy	$147.4B	89.81%	49.73	13.25%
Abbott Laboratories	Buy	$231.0B	65.83%	17.43	31.95%

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

Organization	Insulet
Employees	0
CEO	Dr. James R. Hollingshead Ph.D.
Industry	Health Technology

Management People of Insulet

Name	Title
Dr. James R. Hollingshead Ph.D.	President, CEO & Director
Ms. Lauren Budden	Group VP, Chief Accounting Officer & Controller
Mr. Mark Field	Senior VP & CTO
Mr. John Wodick Kapples J.D.	Senior VP & General Counsel
Mr. Eric Benjamin	Executive VP, Chief Product & Customer Experience Officer
Ms. Ana Maria Chadwick	Executive VP, CFO & Treasurer
Mr. Prem Singh	Senior Vice President of Global Operations
June Lazaroff	Senior Director of Investor Relations
Ms. Laetitia Cousin	Senior VP of Regulatory Affairs, Quality Assurance & Compliance
Ms. Angela Geryak Wiczek	Senior Director of Corporate Communications

Important FAQs about investing in PODD Stock from India :

What is Insulet share price today?

Insulet share price today stands at $282.80, Open: $276.35 ; Previous Close: $288.29 ; High: $286.45 ; Low: $275.32 ; 52 Week High: $289.46 ; 52 Week Low: $160.19.

The stock opens at $276.35, after a previous close of $288.29. The stock reached a daily high of $286.45 and a low of $275.32, with a 52-week high of $289.46 and a 52-week low of $160.19.

Can Indians buy Insulet shares?

Yes, Indians can invest in the Insulet (PODD) from India.

With INDmoney, you can buy Insulet at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Insulet at zero transaction cost.

How can I buy Insulet shares from India?

It is very easy to buy Insulet from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Insulet (PODD) be purchased?

Yes, you can buy fractional shares of Insulet with INDmoney app.

What are the documents required to start investing in Insulet stocks?

To start investing in Insulet, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.